Shots:
- The P-lll SURPASS-1 study involves assessing Tirzepatide as monothx. (5/10/15 mg) vs PBO in 478 patients in the ratio of (1:1:1:1) with T2D inadequately controlled with diet and exercise alone
- Results: A1C reduction: (-1.75% /-1.71%/-1.69% vs- 0.09%); Weight reduction: 6.3/7.0/7.8kg vs 1.0 kg; percentage of participants achieving A1C <7%: 81.8%/84.5%/ 78.3% vs 23.0%; percentage of participants achieving A1C <5.7%: 30.9% /26.8%/38.4% vs 1.4% respectively
- The highest dose led to A1C reduction of 2.07 % with a reduction in body weight by 9.5 kg (11 %), 51.7 % of patients achieved an A1C less than 5.7 %
Click here to read full press release/ article | Ref: PRNewswire | Image: Diario AS
The post Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes first appeared on PharmaShots.
